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Abstract  
Background: Contrast- induced nephropathy (CIN) has gained increasing attention in 
clinical practice,  par ticular ly during coronary angiography (CAG). However, some 
“bioequivalent”  generic (GE) drugs are less effective than the innovator  ( IN) drug. 
Therefore, the aim of this study was to compare contrast media (IN drug)- induced renal 
dysfunction to contrast media (GE drug)-induced dysfunction.  
Methods and Results :  We enrolled 44 patients who underwent elective CAG or  
percutaneous coronary intervention (PCI) and randomly divided them into two groups that  
received contrast media (Iohexol,  non-ionic and low-osmolality contrast agent) containing 
either  IN drug (Omnipaque®) or  GE drug (Iopaque®). Blood and urine sampling were 
performed before and after (24h and 48 h) CAG or PCI. Biochemical parameters in blood 
[serum creatinine,  cystatin C, high sensitive-C reactive protein and pentraxin-3]  and urine 
[urinary albumin/Cr and liver-type fatty acid binding protein/Cr]  were measured. There were 
no significant differences in the biochemical parameters at baseline between the groups.  In 
addition, there were no differences in changes in biochemical parameters in blood and urine 




Conclusion:  The degree of contrast in Iopaque®-induced renal dysfunction was comparable 
to that in Omnipaque®-induced dysfunction.  





Contrast- induced nephropathy (CIN) has gained increasing attention in clinical practice  
(1-3) . CIN refers to the acute deter ioration of renal function seen after the administration of  
contrast media  in the absence of other  causes.  Coronary stent implantation reduces  
restenosis after percutaneous coronary intervention (PCI)  in patients with coronary ar tery 
disease (CAD) (4-6) . Coronary angiography (CAG) also uses contrast media and is an 
important technique for the diagnosis and treatment of coronary restenosis.  
Contrast media  have direct toxic effects on renal tubular cells,  and cause vacuolization,  
altered mitochondrial function and apoptosis (7). High-r isk patients,  such as older  patients 
and those with diabetes mellitus (DM) and congestive heart fa ilure, have a  higher incidence 
of CIN (calculated to be 15-25 %) than that in the general population (about 2-3%) (8-11).  
Patients with CAD are a t high r isk and may have a  higher  rate of CIN. Renal fa ilure after  
the administra tion of contrast media  that requires in-hospita l dia lysis is associated with a  
poor  outcome, including in-hospita l mortality and poor  two-year  survival (9,  12) .  Thus,  we 
need to prevent CIN in patients who undergo CAG or  PCI.  
The use of generic (GE) drugs has been increasing,  pr imarily as a  cost-saving measure in 
healthcare.  GE drugs are typically 20 to 90% less expensive than the equivalent innovator  
(IN) drugs.  The application of GE drugs is typically based on chemical-pharmaceutical data  
and the results of bioequivalence studies, which demonstrate that the GE product is similar  
to the reference medicine (13) . On the other  hand, previous studies have shown that some 
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“bioequivalent”  GE drugs are less effective than the IN drugs (13-15) . In addition, i t is not  
known whether  the degree of contrast media (GE drug)- induced renal dysfunction is similar  
to that of contrast media  (IN drug)- induced dysfunction.  
Although CIN was defined in terms of serum creatinine (S-Cr),  renal injury can also be 
assessed by high-sensitivity biomarkers,  such as serum cystatin-C (Cys-C) (16-18)  and 
ur inary L-type fa tty acid binding protein (L-FABP) (19-21) . In addition,  pentraxin-3 (PTX-
3) is an inflammatory maker  that is more sensitive than C-reactive protein (CRP) for the  
direct assessment of vascular  injury (22).  
Therefore, the a im of this study was to compare contrast media (IN drug)- induced renal  
dysfunction to contrast media (GE drug)-induced dysfunction using high-sensitivity 




We prospectively enrolled 44 patients who underwent elective percutaneous  
catheterization (CAG or  PCI) because of suspected CAD at Fukuoka University Hospita l.  
Patients who were ≥80 y old, and those who showed hemoglobin A1c >8.0 %, S-Cr >1.5 
mg/dL or  a past history of a llergy to contrast media were excluded. The remaining patients  
were randomly divided into two groups [contrast media (Iohexol, non-ionic and low-
osmolality contrast agent) containing either  IN drug (Omnipaque®) (n=23, IN group) or GE 
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drug (Iopaque®) (n=21, GE group)]  after adjusting for  several factors [age, gender , body 
mass index (BMI) and S-Cr] . We excluded 4 patients after randomization because 3 in the  
IN group lacked biochemical data and 1 in the GE group did not undergo CAG. Finally, we 
analyzed 40 patients in the IN (n=20) and GE (n=20) groups.  The presence of CAD was 
defined according to significant coronary stenosis (>50 %, at least one coronary vessel) by 
CAG. CIN was a lso defined as an increase in S-Cr of 25 % and/or  0.5 mg/dL within 48 h 
after exposure to the contrast media  (3) . The protocol of  this study was approved by the 
ethics committee of Fukuoka University Hospital, and all  subjects gave their  written 
informed consent to par ticipate.  We collected all  of the patient background data  using the  
medical database  of Fukuoka University Hospita l.  
 
Evaluation of coronary risk factors and patient characterist ics 
We compared the IN and GE groups with regard to coronary risk factors. We checked 
fasting serum samples.  Coronary risk factors included age,  gender , obesity [body mass index 
(BMI)] ,  hypertension (HT),  dyslipidemia (DL), DM and chronic kidney disease (CKD) . 
Patients who had a current systolic blood pressure (SBP)/diastolic BP (DBP) ≥140/90mmHg 
or  who were receiving antihypertensive therapy were considered to have HT. DM was 
defined using the Japan Diabetes Society Criteria or  if the patient was being treated with an 
oral hypoglycemic agent or insulin.  Patients with low-density lipoprotein cholesterol ≥140 
mg/dl, tr iglyceride ≥150 mg/dl, and/or high-density lipoprotein cholesterol <40 mg/dl, or  
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who were receiving lipid- lowering therapy, were considered to have DL. Obesity was  
defined as a BMI >25 kg/m2. The estimated glomerular  fi l tra tion rate (eGFR) was 
determined using the abbreviated equation that the Japanese Society of Nephrology modified 
for Japanese based on the Modification of Diet in Renal Disease Study; 194 x [age (years)]-
0.287 x [serum Cr (mg/dl)]-1.094
 
x [0.739 if female] . CKD was defined as an eGFR <60  
mL/min/1.73m2. Medications included angiotensin II type 1 receptor blocker  
(ARB)/angiotensin converting enzyme inhibitor (ACE-I) , calcium channel blocker (CCB), β-
blocker,  diuretics,  nitroglycerin,  nicorandil,  sta tin and non-steroidal anti- inflammatory 
drugs (NSAIDs).  
 
Measurement of blood and urinary biomarkers 
Blood and urine samples were collected following an overnight fast by standard 
techniques before catheter ization (at baseline) ,  and at 24 h and 48 h after catheterization.   
Biochemical parameters in blood, including complete blood cell count,  l iver  function 
[aspartate aminotransferase (AST), a lanine aminotransferase (ALT)] , renal function [blood 
urea nitrogen (BUN), Cr and Cys-C],  electrolytes [sodium (Na),  potassium (K) and chloride 
(Cl)], creatine kinase (CK), high-sensitivity CRP (hs-CRP) and PTX-3 were determined.  
Urinary (U)-Cr, the ratio of U-albumin (Alb) to U-Cr (U-Alb/U-Cr)  and the ra tio of U-L-
FABP to U-Cr (U-L-FABP/U-Cr)  were also analyzed. The concentrations of PTX-3 in plasma  
and L-FABP in ur ine were determined in duplicate by specific enzyme immunoassays 
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according to the manufacturer ’s instructions (R&D Systems, Minneapolis, MN, and Perseus 
Proteomics Inc.,  Tokyo, Japan).  At our  laboratory,  the intra-  and inter-assay coefficients of  
var ia tion for  these parameters were each < 5 %. 
 
Statistical analysis 
Statistical analysis was performed using the Stat View sta tistical software package (Stat  
View 5; SAS Institute INC.,  Cary,  NC).   Data are expressed as the mean ± standard 
deviation (SD). The significance of differences was evaluated using the unpaired and paired 
t-test for continuous variables and the c2 test for non-continuous variables.  A value of  
p<0.05 was considered significant.  
 
Results 
Baseline patient characterist ics 
Table 1 shows the baseline clinical character istics in the IN and GE groups. In the IN 
group, the percentages (%) of HT, %DM and %DL were 85 %, 50 % and 95 %, respectively.  
There were no differences in these 3 factors between the two groups. In addition, there were 
no differences in %CKD, left ventr icular ejection fraction (LVEF) or  the volume of contrast 
media  used between the two groups.  The GE group had a significantly higher incidence of  
treatment with diuretic than the IN group and the IN group tended to have a higher  
incidence of treatment with nicorandil than the GE group, whereas there were no differences 
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in other medications.  
 
Baseline biochemical parameters in blood and urine 
As shown in Table 2, there were no significant differences in baseline biochemical 
parameters in blood and urine,  including S-Cr, PTX-3, hs-CRP, Cys-C, U-Alb/U-Cr and U-L-
FABP/U-Cr between the IN and GE groups.  
 
Time-courses of various biochemical parameters in blood and urine during the study 
period 
The time-courses of var ious biochemical parameters in blood and urine  are shown in 
Figure 1. The IN group showed significant increases in S-Cr,  Cys-C and U-L-FABP/U-Cr 
after 24 h compared with baseline. The levels of hs-CRP in the IN group after  48 h and in 
the GE group after 24 h and 48 h were significantly increased compared with those a t 
baseline.  
 
Differences in changes in various biochemical parameters in blood and urine before and 
after CAG or PCI 
Next, we analyzed the differences in changes in parameters before and after 24 h CAG or  
PCI between the IN and GE groups (Figure 2) . There were no significant differences in ΔS-
Cr,  ΔCys-C, Δhs-CRP, ΔPTX-3, ΔU-Alb/U-Cr and ΔU-L-FABP/U-Cr between the groups  
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(Δ=the value after  24 h CAG or PCI minus the value at baseline) . We also analyzed the  
differences in changes in the parameters before and after  48 h CAG or PCI between the IN 
and GE groups. There were no significant changes in the parameters after 48 h between the 
groups (data not shown).  
 
Differences in changes in S-Cr before and after CAG or PCI with or without treatment  
with diuretic  or nicorandil 
Since the GE group showed a  significantly higher incidence of treatment with diuretic 
than the IN group and the IN group tended to show a higher incidence of treatment with 
nicorandil than the GE group (Table 1) , we analyzed the differences in ΔS-Cmax (ΔS-Cmax 
= the maximum value of S-Cr a t 24-48 h after CAG or  PCI minus the S-Cr at baseline)  
between patients with and without the use of diuretic or nicorandil (Figure 3) . There were  
no significant differences in ΔS-Crmax between the patients with and without the use of  
diuretic or nicorandil.  
 
Percentage of the patients with CIN or an increase in S-Cr after the use of contrast  
media 
While none of the patients in the IN group had CIN after 48 h (Figure 4a) , 1 patient in the  
GE group (5 %) had CIN (GE group vs.  IN group, p=0.311) . The patient with CIN had DM, 
HT, DL and renal dysfunction (S-Cr a t baseline=1.4 mg/dl) and required a  greater volume of  
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contrast medium (275 ml) compared to the average volume of medium (126 ml) . Since only 
1 of the tota l patients had CIN, we divided the patients into ΔS-Crmax＞0 (n=16) and 0≥ΔS-
Crmax (n=24) (Figure 4b) . The percentages (%) of the patients with ΔS-Crmax＞0 in the IN  
and GE groups were 45 and 35 %, respectively (GE group vs.  IN group, p=0.519).  
 
Discussion 
First,  we found that the degree of Iopaque® (GE drug)- induced ΔS-Cr was comparable to 
that of Omnipaque® (IN drug)-induced ΔS-Cr,  and only 1 patient in the GE group had CIN.  
Second, there were no differences in the changes in high-sensitivity biomarkers (Cys-C, 
PTX-3 and U-L-FABP/U-Cr)  between the GE and IN groups, a lthough these levels increased 
after catheterization.  
In this study, GE drug-induced ΔS-Cr was similar  to IN drug-induced ΔS-Cr.  Since GE 
drugs have the same basic composition and properties as IN drugs (13,  23),  our data  should 
be reasonable. On the other hand, GE drugs are approved without testing by clinical tr ials.  
The validity of the current cr iter ia for the interchangeability of IN and GE drugs remains 
controversial and may compromise the response and/or safety of patients. Previous reports  
have indicated that some “bioequivalent”  GE drugs are less effective than their respective  
IN drugs (14, 15, 23). Since these drugs are therapeutic agents, rather than diagnostic  
reagents like contrast media ,  the effect of GE contrast media in the present study was  
comparable to that of IN contrast media. In addition,  we excluded patients with S-Cr >1.5  
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mg/dL and enrolled patients with either normal renal function or only mild renal dysfunction.  
We selected patients who underwent elective catheter ization,  but not emergency 
catheterization,  a lthough emergency PCI has been shown to be a risk factor for CIN (24, 25) .  
Finally,  we used Iohexol,  which is a non-ionic  and low-osmolality contrast media,  in this 
study because the type of contrast media used in patients with renal impairment may 
minimize the onset of CIN (8). These factors may make it difficult to distinguish between 
the effects of IN and GE drugs.  This fact may also be associated with the fact that only 1 
patient in the present study had CIN (2.5 %), whereas high-risk patients in previous reports 
have shown a  higher incidence of CIN (15-25 %) (8-11) .  
The level of S-Cr is a  definitive parameter  for  the diagnosis of CIN (3) .  There are many 
useful parameters for the evaluation of renal function, such as Cys-C and U-L-FABP/U-Cr .  
Cys-C is more sensitive than S-Cr for rapidly detecting acute changes in renal function (16,  
17). Liu et al. suggested that the increase in Cys-C reaches a maximum within 24 h after  
exposure to contrast media (18). Although we also observed significant differences in 
changes in Cys-C after 24 h in the IN group, there was no difference between the IN and GE 
groups. Moreover, the endothelia l toxicity of contrast media induces endothelial dysfunction 
as well as inflammation,  oxidative stress, thrombosis,  and altered vasomotor  balance (7, 26) .  
U-L-FABP is upregulated by stresses such as ischemia, toxins and an increase in free fa tty 
acids (19) and can be used to help predict and monitor the progression of renal disease (20).  
The levels of U-L-FABP/U-Cr were a lso significantly increased after  24 h in the IN group,  
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and there were no significant differences in the changes in U-L-FABP/U-Cr between the 
groups. Thus,  there were no differences in renal function after  exposure to contrast media ,  
despite the use of two excellent clinical markers. We also analyzed inflammatory markers ,  
such as hs-CRP and PTX-3. Although both hs-CRP and PTX-3 significantly increased after  
24 h in a ll patients (p<0.01 and p<0.05, respectively) , there were no differences between the 
IN and GE groups.  Since PTX-3 is a  short form of CRP and an acute-phase reactant that i s  
produced at the site of inflammation by macrophages, dendritic cells,  neutrophils,  
fibroblasts,  endothelia l cells and smooth muscle cells (22) , contrast media  may influence the  
activation of these cells.  
In this study, the GE group had a  significantly higher  incidence of treatment with diuretic  
and the IN group tended to have a higher incidence of treatment with nicorandil, although 
we randomly divided the patients into the IN and GE groups using computer  software .  
Diuretic therapy, in addition to aging, DM, baseline renal insufficiency, higher  doses of  
contrast media and so on, is associated with a higher r isk of CIN (27, 28) .  Nicorandil is an 
ATP-sensitive potassium (KATP) channel agonist and a  nitr ic oxide donor. KATP channel  
reduces renal injury due to ischemia and reperfusion, which suggests that nicorandil may 
protect the kidney from ischemic injury associated with the use of contrast media  (29,  30) .  
Although diuretic and nicorandil therapy may affect renal function after the use of contrast  
media , there were no significant differences in ΔS-Crmax between the patients with and 
without the use of diuretic or  nicorandil.  
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GE drugs serve as lower-cost a lternatives to the more costly IN drugs used in clinical 
medicine today. The IN drug (Omnipaque®) and the GE drug (Iopaque®) used in the present 
study cost 9,358 and 7,430 yen/100mL, respectively.  Since the average volumes of contrast  
media  used in this study for the IN and GE drugs were 125.7 and 125.2 mL/person,  
respectively,  the total costs of the IN and GE drugs were 11,763 and 9,302 yen/person,  
respectively.  This difference (2,461 yen/person)  represents a significant cost savings.  
There are many stra tegies for the prevention of  CIN after  the use of contrast media  e.g.,  
hydration, and the administra tion of mannitol and furosemide (9,  31-33).   Although 
therapeutic prevention stra tegies are being extensively investigated,  there is sti l l no 
definitive answer (9).  In this study, the patients did not receive specific treatments for  the  
prevention of CIN and received only a standard infusion of intravenous fluids. There was no 
difference in the volume of infusion between the IN and GE groups.  In addition,  the 
development of CIN seems to depend on the amount of contrast agent given. However, there  
was no difference in the volume of contrast media  between the IN and GE groups,  and the  
volume was lower than in previous reports (32-34).  
This study has several study limita tions.  First, the sample size was relatively small.  
However, we randomly divided the patients into IN and GE groups after  adjusting for  
several cr itical factors (age, gender, BMI and S-Cr). Second, the measurements were  
performed under  var ious oral medications.  Although many of the patients were taking 
diuretics and NSAIDs that might influence the onset of CIN, there was no significant 
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difference in % NSAIDs between the IN and GE groups.  In addition,  there were no 
differences in ΔS-Cr, ΔCys-C, Δhs-CRP, ΔPTX-3, ΔU-Alb/U-Cr or ΔU-L-FABP/U-Cr  
between patients with and without the use of diuretics or nicorandil.  
In conclusion, the degree of contrast in Iopaque® (GE drug)- induced renal dysfunction 
was comparable to that in Omnipaque® (IN drug)-induced dysfunction.  
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Figure 1.  
Time-courses of var ious biochemical parameters in blood and urine during the study period 
in the IN (black lines) and GE (gray lines) groups.  *p<0.05 vs.  before CAG or PCI (a t 
baseline).  
 
Figure 2.  
Differences in changes in var ious biochemical parameters in blood and ur ine before and 24 h 
after CAG or PCI in the IN (black bars) and GE (gray bars) groups.Δ indicates the value 24  
h after CAG or PCI minus the value at baseline. N.S.,  not significant.  
 
Figure 3.  
Differences in changes in S-Cr between before and after CAG or  PCI with (dotted bars)  or  
without (open bars)  treatment with diuretic (a) or  nicorandil (b).ΔS-Crmax indicates the 
maximum value of S-Cr at 24-48 h after CAG or PCI minus S-Cr at baseline. N.S., not  
significant.  
 
Figure 4.  
Percentages (%) of CIN (a)  and the patients with ΔS-Crmax＞0 (b) in the IN (black bars)  
23 
 
and GE (gray bars) groups.ΔS-Crmax indicates the maximum value of S-Cr at 24-48 h after  
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IN (N=20) GE (N=20) P value
Age, yrs 68±9 72±6 0.09
Male, % 75 65 0.50
BMI, kg/m² 23±3 23±3 0.85
HT, % 85 100 0.07
DM, % 50 30 0.21
DL, % 95 90 0.56
CKD, % 35 40 0.75
CAD, % 95 90 0.55
LVEF, % 61±14 64±11 0.58
Volume of contrast medium, mL 126±63 125±67 0.98
Infusion volume of intravenous 
fluids, ml 1375±425 1350±813 0.90
Table 1. Patient characteristics.
IN, innovator; GE, Generic; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; DL,
dyslipidemia; CKD, chronic kidney disease; CAD, coronary artery disease; LVEF, left ventricular ejection
fraction; ARB, angiotensin II type 1 receptor blocker; ACE-I, angiotesin converting enzyme inhibitor; CCB,
calcium channel blocker; NSAIDs, non-steroidal anti-inflammatory drugs.
Medication
ARB/ACE-I, % 75 65 0.50
CCB, % 60 65 0.75
b-blocker, % 15 15 0.99
Diuretic, % 5 30 0.04
Nitroglycerin, % 25 10 0.22
Statin, % 80 85 0.69
Nicorangil, % 40 15 0.08
NSAIDs, % 35 15 0.15
IN (N=20) GE (N=20) P value
WBC, /μL 5470±1422 5905±1737 0.39
Hb, g/dL 13.0±1.7 13.0±1.5 0.93
BUN, mg/dL 16.1±4.6 17.6±4.7 0.33
Cr, mg/dL 0.9±0.2 0.9±0.2 0.79
eGFR, ml/min/1.73m² 64.9±14.4 61.4±14.0 0.44
Na, mEq/L 140±3 140±2 0.90
K, mEq/L 4.2±0.4 4.3±0.5 0.88
Cl, mEq/L 101±2 105±3 0.36
AST, IU/L 23±6 24±6 0.45
ALT, IU/L 23±11 25±13 0.63
CK, IU/L 116±106 84±37 0.22
hs-CRP, mg/dL 0.13±0.16 0.25±0.45 0.30
PTX-3, ng/mL 2.0±1.02 2.3±0.9 0.41
Cys-C, mg/L 1.0±0.3 1.0±0.3 0.58
U-Cr, mg/dL 81±38 83±64 0.88
U-Alb/U-Cr, mg/gCr 17±21 20±54 0.84
U-L-FABP/U-Cr, μg/gCr 0.06±0.03 0.09±0.11 0.21
Table 2. Baseline biochemical parameters in blood an urine.
IN, innovator; GE, Generic; WBC, white blood cell; Hb, hemoglobin; BUN, blood urea nitrogen; Cr,
creatinine; eGFR, estimated glomerular filtration rate; Na, sodium; K, potassium; Cl, chloride; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase; hs-CRP, high-sensitive
C-reactive protein; PTX-3, pentraxin-3; Cys-C, cystatin-C; U-Cr, urinary creatinine; U-Alb/U-Cr, U-
albumin/U-Cr; U-L-FABP/U-Cr, U-L-type fatty acid binding protein/U-Cr.
